All news

ARK rotates $22 million, extends Intellia buying streak

Alpha Vantage · BigGo Finance · · AI-summarised by FinFlash

Cathie Wood's ARK Invest executed a roughly $22 million healthcare portfolio rotation, selling Twist Bioscience while buying Recursion Pharmaceuticals, Intellia Therapeutics and Veracyte. The shift favors genomics companies with nearer-term clinical and diagnostic catalysts rather than signaling a retreat from biotech. ARK extended its Intellia buying streak to 50 consecutive sessions, ahead of an FDA decision on the company's CRISPR therapy expected in March 2027. Analysts carry an average target of $24.00 versus a

Read original source

NTLA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.